ERBB2 and obstructive sleep apnea syndrome: Importantly for the comparative oncology field, the positive results obtained in canine patients led to a Phase Ib clinical trial utilizing this vaccine, named ADXS31-164, in adult patients with HER2-expressing tumors (NCT02386501), and it has now been licensed for development in the pediatric OSA setting by OS Therapies in conjunction with the NCI Children’s Oncology Group [141].